Communiqués Pharma Equity Group A/S

Actions

PEG A

DK0061155009

Temps Différé Nasdaq Copenhagen Autres places de cotation 16:45:24 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,296 ^DKK	+9,63 %		+24,37 %	-31,16 %

17/05	Pharma Equity Group A/S publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI
16/05	Pharma Equity Group A/S maintient ses prévisions de bénéfices pour l'année 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Results of extraordinary general meeting in Pharma Equity Group A/S	03/06	GL
The Board of Director's decision to issue convertible loans	16/05	GL
Pharma Equity A/S : 2024 Q1 Consolidated Interim Report	16/05	PU
Consolidated interim report 1 January – 31 March 2024	16/05	GL
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S	08/05	GL
Notice convening the extraordinary general meeting of Pharma Equity Group A/S	08/05	GL
Major shareholder announcement - Pharma Equity Group A/S	23/04	GL
Passing of the General Meeting of Pharma Equity Group A/S	16/04	GL
The Board of Director's decision to issue convertible loans	10/04	GL
Pharma Equity A/S : Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051.	05/04	PU
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.	05/04	GL
Notice convening the annual general meeting in Pharma Equity Group A/S	25/03	GL
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009	22/03	GL
Completion of subscription of convertible loans	21/03	GL
Correction: Pharma Equity Group A/S - Annual Report 2023	20/03	GL
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).	05/03	GL
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).	05/03	AQ
Completion of subscription of convertible loans	07/02	GL
The Board of Director's decision to issue convertible loans	07/02	GL
Completion of subscription of convertible loans	25/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Pharma Equity Group A/S

Actions

PEG A

DK0061155009

Communiqués

Filtres